Reports Q2 revenue $163.353M, consensus $149.82M. “The financial performance this quarter is the best in the company’s history resulting from better-than-expected revenue growth and very meaningful operating profit. In the fifth year since approval, ORLADEYO revenue and demand have never been stronger, and this is driven by outstanding execution and increasing confidence in the product. Our accelerating operating profit and the sale of our European ORLADEYO business strengthen our financial position to deliver even greater value, and our pipeline remains on track for initial data later this year in two clinical programs,” said Jon Stonehouse, chief executive officer of BioCryst (BCRX).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- BioCryst Announces New President Amid Leadership Change
- BioCryst announces planned retirement of CEO Stonehouse, Gayer to succeed
- BioCryst Pharmaceuticals’ BCX9930 Study Termination: Implications for Investors
- BioCryst Appoints New CFO to Drive Growth